Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
- About
Aardvark Therapeutics, Inc. Common Stock (AARD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: AARD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $
1 Year Target Price $
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 26% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 284.41M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 4.88 - 19.58 | Updated Date 05/31/2025 |
52 Weeks Range 4.88 - 19.58 | Updated Date 05/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.65 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 202920214 | Price to Sales(TTM) - |
Enterprise Value 202920214 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 21384400 | Shares Floating 18389495 |
Shares Outstanding 21384400 | Shares Floating 18389495 | ||
Percent Insiders 24.03 | Percent Institutions 24.9 |
Analyst Ratings
Rating 4.5 | Target Price - | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Aardvark Therapeutics, Inc. Common Stock
Company Overview
History and Background
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for metabolic diseases, including obesity and non-alcoholic steatohepatitis (NASH). Founded to address unmet medical needs in these areas, the company is advancing a pipeline of oral small molecule therapeutics.
Core Business Areas
- Metabolic Disease Therapeutics: Development and commercialization of small molecule therapies for metabolic disorders like obesity and NASH. Focus is on oral medications that modulate key metabolic pathways.
Leadership and Structure
The company's leadership team consists of executives with experience in drug development, regulatory affairs, and commercialization. The organizational structure is typical of a clinical-stage biotech, emphasizing research and development.
Top Products and Market Share
Key Offerings
- ARD-101: A first-in-class oral small molecule being developed for the treatment of obesity-related diseases and NASH. Currently in Phase 2 clinical trials. Market share data is not yet available as the product is pre-commercial. Competitors include companies developing GLP-1 receptor agonists and other weight-loss drugs such as Novo Nordisk (NVO) and Eli Lilly (LLY).
Market Dynamics
Industry Overview
The market for obesity and NASH therapeutics is large and growing rapidly, driven by increasing prevalence of these diseases. The industry is characterized by significant unmet need and increasing investment in new therapies.
Positioning
Aardvark Therapeutics is positioning itself as an innovator in metabolic disease therapeutics, focusing on oral small molecule therapies with differentiated mechanisms of action.
Total Addressable Market (TAM)
The TAM for obesity and NASH therapeutics is estimated to be tens of billions of dollars. Aardvark is positioned to capture a portion of this market with successful development and commercialization of ARD-101. It has a novel approach compared to standard of care.
Upturn SWOT Analysis
Strengths
- Novel drug candidate (ARD-101)
- Experienced management team
- Targeting large and growing markets (obesity, NASH)
- Oral drug candidate (patient convenience)
Weaknesses
- Clinical-stage company (high risk of failure)
- Limited financial resources
- Dependence on a single lead product
- No current revenue stream
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into other metabolic disease indications
- Regulatory approvals for ARD-101
Threats
- Clinical trial failures
- Competition from other companies
- Regulatory hurdles
- Financing risks
Competitors and Market Share
Key Competitors
- NVO
- LLY
- GILD
- MRK
Competitive Landscape
Aardvark Therapeutics faces competition from larger pharmaceutical companies with more advanced pipelines and greater financial resources. Its advantage lies in its novel mechanism of action and oral delivery.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by advancement of ARD-101 through clinical trials.
Future Projections: Future growth is dependent on successful clinical trial outcomes and potential commercialization of ARD-101. Analyst estimates are speculative and vary.
Recent Initiatives: Recent initiatives include ongoing Phase 2 clinical trials for ARD-101.
Summary
Aardvark Therapeutics is a high-risk, high-reward clinical-stage company. Its strength is its novel drug candidate targeting large markets. Its weaknesses lie in its limited resources and dependence on clinical trial success. The company needs to secure partnerships and manage its cash burn carefully.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Information is based on publicly available data and subject to change. Investment in clinical-stage biotechnology companies is highly speculative and involves significant risk of loss.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aardvark Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2025-02-13 | CEO, Secretary & Director Dr. Tien-Li Lee M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 26 | Website https://aardvarktherapeutics.com |
Full time employees 26 | Website https://aardvarktherapeutics.com | ||
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in the Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from the treatment of craniopharyngioma, including surgery or radiation. The company is also developing ARD-201, which is in the Phase 1 clinical trial for the treatment of obesity. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.